These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32718047)

  • 1. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma.
    Gong J; Chuang J; Cho M; Toomey K; Hendifar A; Li D
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targeted therapy for hepatocellular carcinoma: current and future.
    Shin JW; Chung YH
    World J Gastroenterol; 2013 Oct; 19(37):6144-55. PubMed ID: 24115810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.
    Han LL; Lv Y; Guo H; Ruan ZP; Nan KJ
    World J Gastroenterol; 2014 Aug; 20(30):10249-61. PubMed ID: 25132742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
    Frau M; Biasi F; Feo F; Pascale RM
    Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response.
    Burkhart RA; Ronnekleiv-Kelly SM; Pawlik TM
    Surg Oncol; 2017 Jun; 26(2):138-145. PubMed ID: 28577719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New landscapes and horizons in hepatocellular carcinoma therapy.
    Cervello M; Emma MR; Augello G; Cusimano A; Giannitrapani L; Soresi M; Akula SM; Abrams SL; Steelman LS; Gulino A; Belmonte B; Montalto G; McCubrey JA
    Aging (Albany NY); 2020 Feb; 12(3):3053-3094. PubMed ID: 32018226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicines: a theranostic approach for hepatocellular carcinoma.
    Usmani A; Mishra A; Ahmad M
    Artif Cells Nanomed Biotechnol; 2018 Jun; 46(4):680-690. PubMed ID: 28884605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
    Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
    J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
    Lin D; Wu J
    World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
    Zhang X; Ng HLH; Lu A; Lin C; Zhou L; Lin G; Zhang Y; Yang Z; Zhang H
    Nanomedicine; 2016 May; 12(4):853-869. PubMed ID: 26772424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting integrins in hepatocellular carcinoma.
    Wu Y; Qiao X; Qiao S; Yu L
    Expert Opin Ther Targets; 2011 Apr; 15(4):421-37. PubMed ID: 21332366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on clinical trials in the treatment of advanced hepatocellular carcinoma.
    Lee JK; Abou-Alfa GK
    J Clin Gastroenterol; 2013 Jul; 47 Suppl():S16-9. PubMed ID: 23751800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma.
    Sato K; Mori M
    Curr Med Chem; 2011; 18(28):4375-88. PubMed ID: 21861817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
    Stotz M; Gerger A; Haybaeck J; Kiesslich T; Bullock MD; Pichler M
    Anticancer Res; 2015 Nov; 35(11):5737-44. PubMed ID: 26503994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
    Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
    Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.